Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoo-Hong Min

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Acta Haematologica|June 13, 2015
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic SyndromeJae-Sook Ahn, Yeo-Kyeoung Kim, Yoo Hong Min, et al.
Annals of Hematology|June 29, 2013
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in KoreaJin Seok Kim, June-Won Cheong, Yeo-Kyeoung Kim, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridizationHye Ryun Lee, Bora Oh, Dae Sik Hong, et al.
European Journal of Haematology|March 17, 2009
Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromesChan H Park, Bruce F Kimler, Seong Yoon Yi, et al.
Annals of Hematology|June 23, 2009
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidineDae-Young Kim, Je-Hwan Lee, Jung-Hee Lee, et al.
British Journal of Haematology|February 26, 2013
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromesYun-Gyoo Lee, Inho Kim, Sung-Soo Yoon, et al.
Haematologica|July 29, 2010
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II studySeok Jin Kim, Jong Wook Lee, Chul Won Jung, et al.
Transfusion|December 10, 2013
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemiaJune-Won Cheong, Hyeoung-Joon Kim, Kyoo-Hyung Lee, et al.
Scientific Reports|November 19, 2020
RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemiaTaeHyung Kim, Joon Ho Moon, Jae-Sook Ahn, et al.
Plos One|November 9, 2016
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeKoung Jin Suh, June-Won Cheong, Inho Kim, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Acta Haematologica|June 13, 2015
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic SyndromeJae-Sook Ahn, Yeo-Kyeoung Kim, Yoo Hong Min, et al.
Annals of Hematology|June 29, 2013
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in KoreaJin Seok Kim, June-Won Cheong, Yeo-Kyeoung Kim, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridizationHye Ryun Lee, Bora Oh, Dae Sik Hong, et al.
European Journal of Haematology|March 17, 2009
Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromesChan H Park, Bruce F Kimler, Seong Yoon Yi, et al.
Annals of Hematology|June 23, 2009
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidineDae-Young Kim, Je-Hwan Lee, Jung-Hee Lee, et al.
British Journal of Haematology|February 26, 2013
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromesYun-Gyoo Lee, Inho Kim, Sung-Soo Yoon, et al.
Haematologica|July 29, 2010
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II studySeok Jin Kim, Jong Wook Lee, Chul Won Jung, et al.
Transfusion|December 10, 2013
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemiaJune-Won Cheong, Hyeoung-Joon Kim, Kyoo-Hyung Lee, et al.
Scientific Reports|November 19, 2020
RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemiaTaeHyung Kim, Joon Ho Moon, Jae-Sook Ahn, et al.
Plos One|November 9, 2016
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeKoung Jin Suh, June-Won Cheong, Inho Kim, et al.
Pageof 13